Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Complications of Depression...
- Diagnosis
- Treatment
- Antidepressants and Drug Tr...
- Psychotherapy
- Other Treatments
- Lifestyle Changes
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the Food and Drug Administration (FDA) approved the atypical antipsychotic drug aripiprazole (Abilify) for treatment of major depression in adults. Aripiprazole is used for treatment of schizophrenia and bipolar disorder. For depression, it is used in combination with antidepressant drug therapy.
- 5 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Symptoms
- Diagnosis
- Outlook
- Staging and Treatment Guide...
- Treatment Options by Stage...
- Radiation Treatments
- Chemotherapy
- Transplantation
- Immunotherapy
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
Chemotherapy can cause anemia, a drop in red blood cell (hemoglobin) levels. Erythropoiesis-stimulating drugs, which boost the production of red blood cells, are administered to counteract this complication. However, these drugs, including epoietin alfa (Epogen, Procrit) and darbepoietin alfa (Aranesp), can also cause serious side effects and adversely affect survival when hemoglobin levels are raised too high.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Causes
- Prognosis
- Diagnosis
- Treatment
- Medications
- Other Treatments
- Therapy and Lifestyle Chang...
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the FDA approved risperidone (Risperdal) for short-term treatment of manic or mixed episodes of bipolar I disorder in children ages 10 - 17. Risperidone (an atypical antipsychotic) and lithium (a mood stabilizer) are the two drugs currently approved for treating pediatric patients with bipolar disorder.
Drug Warnings
- Olanzapine (Zyprexa, Symbex) causes a greater risk for high blood sugar than other atypical antipsychotics, according to updated information added to the drug’s warning label.
- 1 Comment
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Symptoms
- Causes
- Risk Factors
- Diagnosis
- Outlook
- Treatment
- Home Management
- Treatment to Achieve Remiss...
- Treatment During Remission...
- Treatment After Relapse
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Acute Lymphocytic Leukemia (ALL)
There are four major types of leukemia. ALL is the most common type of leukemia diagnosed in children, and the least common type diagnosed in adults. About 5,200 people are diagnosed with ALL each year.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Symptoms
- Diagnosis
- Outlook
- Staging and Treatment Guide...
- Chemotherapy
- Biologic Therapy (Immunothe...
- Radiation
- Transplantation
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
Chemotherapy can cause anemia, a drop in red blood cell (hemoglobin) levels. Erythropoiesis-stimulating drugs, which boost the production of red blood cells, are administered to counteract this complication. However, these drugs, which include epoietin alfa (Epogen, Procrit) and darbepoietin alfa (Aranesp), can also cause serious side effects and adversely affect survival when hemoglobin levels are raised too high.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Prognosis
- Risk Factors
- Symptoms
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Symptoms
- Causes
- Prognosis
- Risk Factors
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Symptoms
- Risk Factors
- Prognosis
- Diagnosis
- Treatment
- Other Treatments
- Decongestants
- Antihistamines
- Corticosteroids
- Immunotherapy
- Prevention
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
Ciclesonide (Omanaris), a corticosteroid nasal spray, has been approved for treatment of seasonal and perennial allergic rhinitis (hay fever) in adults and children age 12 years and older.
FDA Drug Warnings
- The antihistamine promethazine (Phenergan) should not be given to children younger than age 2 because it may cause serious breathing problems.
- Omalizumab (Xolair) may cause a life-threatening allergic reaction (anaphylaxis). This drug is used to treat allergy-related asthma, but is also being investigated as an allergy treatment.
Cough and Cold Medicines for Children
In 2007, the FDA began reviewing the safety and effectiveness of cough and cold medicines for children.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Complications
- Diagnosis
- Prevention
- Treatment for Acute Sinusit...
- Treatment for Chronic Sinus...
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Restriction
In February 2007, the FDA announced that the antibiotic telithromycin (Ketek) should no longer be used for treatment of acute bacterial sinusitis. In June 2006, the FDA reported that several people had died of liver damage after taking this drug. Telithromycin is now only approved for treatment of community-acquired pneumonia.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Blemishes
- Risk Factors
- Prevention
- Treatment
- Resurfacing Treatments
- Implant Procedures
- Plastic Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Smoking and Skin Damage
- The skin of smokers ages more rapidly than the skin of non-smokers, even in areas of the body not exposed to sunlight, according to a 2007 study. Women in the study who smoked also had much lower levels of vitamin E secretions in their skin. Vitamin E may protect the skin from sun damage.
- There may be an association between smoking and higher frequency of a type of acne (noninflammatory acne) in adult women, according to a European study.
Antioxidants and Your Skin
- A study in the Journal of Nutrition found that a combination of antioxidants and trace elements supplementation raises the risk of skin cancer in women, but not in men.
Ultraviolet Radiation
- Overall, exposure to ultraviolet radiation from sunlight (radiation referred to as UVA or UVB) accounts for about 90% of the symptoms of premature skin aging.
- UVB primarily affects the outer skin layers.
- 0 Comments
Schuh
Matches Fashion
Miss Sixty